InMed Pharmaceuticals Inc. has officially changed its name to Mentari Therapeutics, Inc. This name change follows the approval of various proposals during the company's recent shareholder meeting, which took place on November 4, 2026. The restructuring is part of a broader strategy to enhance operational efficiency and adapt to the evolving landscape of the pharmaceutical preparations industry.

The name change and restructuring are significant for InMed, as they mark a pivotal shift in the company's direction. By rebranding to Mentari Therapeutics, the company aims to better align its corporate identity with its strategic goals following the merger with Mentari Therapeutics, Inc., a Delaware corporation. This merger was initially announced on May 19, 2026, and has now reached a critical phase with the completion of necessary shareholder approvals.

Background

InMed Pharmaceuticals Inc., categorized under the SIC code 2834, specializes in pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol INM. Recent filings indicate that InMed has been active in restructuring its operations and capitalizing on growth opportunities within the pharmaceutical sector.

What the Filing Says

The recent SEC filing, accession number 0001193125-26-448367, details the outcomes of the shareholder meeting held on November 4, 2026. During this meeting, shareholders approved several key proposals, including:

"The Company’s shareholders approved the issuance of the Common Shares, including the Common Shares issuable upon conversion of the Series A Preferred Shares, which will represent more than 20% of the Common Shares outstanding immediately prior to the First Merger."

This approval allows for the completion of the merger with Mentari, enabling InMed to transition into Mentari Therapeutics, Inc.

Impact

The changes are expected to have a substantial impact on shareholders and the company's future operations. With the merger, Mentari will continue as a wholly owned subsidiary, and the new corporate structure aims to streamline operations and enhance shareholder value. The consolidation of shares and the introduction of non-voting convertible preferred shares are also designed to provide flexibility in capital management.

What's Next

The filing does not specify what happens next, but the completion of the merger and the name change are expected to be effective immediately. The company will continue to operate under its new name on the Nasdaq, and further updates may follow as the integration of operations progresses.